Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer’s Disease: A 5-Year Follow-up Study

2016 ◽  
Vol 55 (2) ◽  
pp. 509-520 ◽  
Author(s):  
Bing Xie ◽  
Zanchao Liu ◽  
Lei Jiang ◽  
Wei Liu ◽  
Mei Song ◽  
...  
2020 ◽  
Vol 17 ◽  
Author(s):  
Hyung-Ji Kim ◽  
Jae-Hong Lee ◽  
E-nae Cheong ◽  
Sung-Eun Chung ◽  
Sungyang Jo ◽  
...  

Background: Amyloid PET allows for the assessment of amyloid β status in the brain, distinguishing true Alzheimer’s disease from Alzheimer’s disease-mimicking conditions. Around 15–20% of patients with clinically probable Alzheimer’s disease have been found to have no significant Alzheimer’s pathology on amyloid PET. However, a limited number of studies had been conducted this subpopulation in terms of clinical progression. Objective: We investigated the risk factors that could affect the progression to dementia in patients with amyloid-negative amnestic mild cognitive impairment (MCI). Methods: This study was a single-institutional, retrospective cohort study of patients over the age of 50 with amyloidnegative amnestic MCI who visited the memory clinic of Asan Medical Center with a follow-up period of more than 36 months. All participants underwent brain magnetic resonance imaging (MRI), detailed neuropsychological testing, and fluorine-18[F18]-florbetaben amyloid PET. Results: During the follow-up period, 39 of 107 patients progressed to dementia from amnestic MCI. In comparison with the stationary group, the progressed group had a more severe impairment in verbal and visual episodic memory function and hippocampal atrophy, which showed an Alzheimer’s disease-like pattern despite the lack of evidence for significant Alzheimer’s disease pathology. Voxel-based morphometric MRI analysis revealed that the progressed group had a reduced gray matter volume in the bilateral cerebellar cortices, right temporal cortex, and bilateral insular cortices. Conclusion: Considering the lack of evidence of amyloid pathology, clinical progression of these subpopulation may be caused by other neuropathologies such as TDP-43, abnormal tau or alpha synuclein that lead to neurodegeneration independent of amyloid-driven pathway. Further prospective studies incorporating biomarkers of Alzheimer’s diseasemimicking dementia are warranted.


2016 ◽  
Vol 52 (1) ◽  
pp. 133-143 ◽  
Author(s):  
María Eugenia López ◽  
Agustín Turrero ◽  
Pablo Cuesta ◽  
David López-Sanz ◽  
Ricardo Bruña ◽  
...  

2018 ◽  
Vol 46 (3-4) ◽  
pp. 140-153 ◽  
Author(s):  
Michele Lauriola ◽  
Antonio Mangiacotti ◽  
Grazia D’Onofrio ◽  
Leandro Cascavilla ◽  
Francesco Paris ◽  
...  

Background/Aim: The aim of the study was to evaluate the prognostic power of late-life depression (LLD) compared with amnestic mild cognitive impairment (aMCI) for the onset of Alzheimer’s disease (AD) within 4 years of follow-up. Methods: We estimated the incidence of AD in 60 patients presenting with aMCI, 115 patients suffering of LLD treated with antidepressants with good compliance, and 66 healthy control (HC) patients, followed for 4 years. Results: The risk to develop AD, within 4 years, was 68.33% for aMCI and 49.57% for LLD. In AD patients 5.60% deteriorated without depression, and 72.20% deteriorated with depression after 4 years of follow-up (p < 0.0001). No HC patients deteriorated to AD or any other dementia type. Conclusion: In our results, aMCI was the first predictive condition that increased the risk to develop AD. Depression is a potentially preventable medical condition across the lifespan and may be a modifiable risk factor.


2012 ◽  
Vol 8 (4S_Part_12) ◽  
pp. P434-P434
Author(s):  
Sebastian Palmqvist ◽  
Joakim Hertze ◽  
Lennart Minthon ◽  
Carina Wattmo ◽  
Kaj Blennow ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document